TERN
Terns Pharmaceuticals Inc

1,943
Loading...
Loading...
News
all
press releases
Buy Rating Affirmed for Terns Pharmaceuticals Amid Positive Forecasts for Obesity Drug TERN-601
JMP Securities analyst Silvan Tuerkcan has reiterated their bullish stance on TERN stock, giving a Buy rating on August 21. Silvan Tuerkcan has giv...
TipRanks Financial Blog·1y ago
News Placeholder
More News
News Placeholder
Analyst Forecasts Terns Pharmaceuticals' Upcoming CML Trial Data as Catalyst for Growth
Analyst Etzer Darout of BMO Capital reiterated a Buy rating on Terns Pharmaceuticals (TERN Research Report), retaining the price target of $19.00...
TipRanks Financial Blog·1y ago
News Placeholder
Terns Pharmaceuticals Announces Executive Shake-up and Strategic Evolution
An update from Terns Pharmaceuticals (TERN) is now available. Terns Pharmaceuticals, Inc. is undergoing a significant executive restructuring with...
TipRanks Financial Blog·1y ago
News Placeholder
Commit To Purchase Terns Pharmaceuticals At $5, Earn 37.2% Annualized Using Options
Investors considering a purchase of Terns Pharmaceuticals Inc (TERN) stock, but tentative about paying the going market price of 6.72/share, might benefit from considering selling puts among the...
Stock Options Channel·1y ago
News Placeholder
UBS Group Cuts Terns Pharmaceuticals (NASDAQ:TERN) Price Target to $18.00
Terns Pharmaceuticals (NASDAQ:TERN - Free Report) had its price target decreased by UBS Group from $19.00 to $18.00 in a research note released on Wednesday morning, Benzinga reports. UBS Group...
Ticker Report·1y ago
News Placeholder
Buy Rating on Terns Pharmaceuticals Amid Promising Developments in Obesity Treatment Sector
Mizuho Securities analyst Graig Suvannavejh reiterated a Buy rating on Terns Pharmaceuticals (TERN Research Report) on March 27 and set a price t...
TipRanks Financial Blog·1y ago
News Placeholder
Terns Pharmaceuticals (NASDAQ:TERN) PT Lowered to $18.00
Terns Pharmaceuticals (NASDAQ:TERN Get Free Report) had its price target reduced by equities research analysts at UBS Group from $19.00 to $18.00 in a report released on Wednesday, Benzinga...
Zolmax·1y ago
News Placeholder
Terns Pharmaceuticals (NASDAQ:TERN) PT Lowered to $15.00
Terns Pharmaceuticals (NASDAQ:TERN Get Free Report) had its price objective lowered by investment analysts at JMP Securities from $17.00 to $15.00 in a research report issued on Monday...
Zolmax·1y ago
News Placeholder
Terns Pharmaceuticals (NASDAQ:TERN) PT Raised to $19.00
Terns Pharmaceuticals (NASDAQ:TERN Get Free Report) had its price objective upped by stock analysts at BMO Capital Markets from $18.00 to $19.00 in a research report issued to clients and...
Ticker Report·1y ago
News Placeholder
Analysts Offer Insights on Healthcare Companies: Terns Pharmaceuticals (TERN) and Spruce Biosciences (SPRB)
Theres a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Terns Pharmaceuticals (TERN Research Report) and Spruce Biosciences...
TipRanks Financial Blog·1y ago

Latest TERN News

View

Advertisement. Remove ads.

Advertisement. Remove ads.